about
Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.Generation of helper-dependent adenoviral vectors by homologous recombination.PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile.Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.Calcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5.Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia BMyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus.Oncolytic viruses for induction of anti-tumor immunity.Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo.Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtinImmune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects.Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytesExpression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunityThe evolution of adenoviral vectors through genetic and chemical surface modifications.Metastatic state of parent cells influences the uptake and functionality of prostate cancer cell-derived extracellular vesicles.Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity.Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus.CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector.Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir.Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver.Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders.Capsid-modified adenoviral vectors for improved muscle-directed gene therapyGenetic diversity and tumor immunesurveillance.Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures.Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates.Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors.Antigen-specific tolerance of human alpha1-antitrypsin induced by helper-dependent adenovirus.AKT participates in endothelial dysfunction in hypertension.In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments.Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients.Correction of murine hemophilia A and immunological differences of factor VIII variants delivered by helper-dependent adenoviral vectors.A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma.Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.
P50
Q30571240-8CECDC3E-A58C-4568-865E-9F55AF4F7313Q33340918-BE810334-B1B9-4A32-A97C-D604231D60A9Q33364520-BAF10DA9-8E42-4CEC-86A9-786D0C0DE758Q33388660-D62C757A-1392-431F-A097-37D3F9482CF8Q33558337-7B53A2B2-4C87-48AD-92F7-30102E5A13A5Q33711997-330EC18E-FEEE-4168-BEAB-2A6A842BBFFCQ33711997-5C37139E-FA2B-40EC-8EFA-7ADEC050CD47Q33747762-CAE4D716-42F2-4D2A-B32D-B6402D017188Q33819902-6B198CAE-9889-4F03-A9F0-95321E72EDC1Q33832157-FF38E4B8-34F6-4580-AC2F-377A11604A9CQ34198912-7401A080-5B89-4F41-8A37-31C63C593EF1Q34205181-E8FBF8D6-C7B5-4DFA-AFBC-35F48824F51FQ35226121-D2DD85D1-9FE2-4F06-9AE8-072997E46014Q36677547-EA3D1125-5CF4-4740-8BA6-B540692BE8E8Q36990088-D42572AA-7B96-462E-A6A2-925A35C7F6A3Q37225109-253C2E95-6E71-481E-B345-F19E8CE4CA9EQ37225198-E93DB1AC-6B77-49C0-8B79-C7DAF25DF7C3Q38189250-3BFEEBA4-B313-4F39-AAC6-259DB84C1AA7Q38694648-37948D87-5C7D-44B6-98BD-99B61ECCD193Q38765125-62D46437-F8C7-4EEF-911C-91D9040A9C5DQ38795358-5C9B37CD-D36E-499E-B756-348993B21C9EQ38923473-CCACABED-CED7-42E5-AA9D-21DE71D35184Q39048893-07F28668-8E8B-412F-AE67-976EB86DC72AQ39508670-3844B7FC-843D-4AB5-8C66-C0B7E8E1222EQ39707831-B47BABEB-AAF2-456F-B9E5-0828414BC4EDQ39880251-6752204D-B524-4E4B-9899-A34F8863AFF4Q40087457-6AC62FEE-E0B2-48C8-AF60-3AFB960E2865Q40438006-88128EB0-14D0-43D4-B04C-7370E2D0C21BQ42254679-5581EBB2-8DFC-4D4B-A4B0-27D6E3414E9FQ42424335-59CB6402-87B5-49E4-9913-47449D67C493Q42784608-416C51BB-A7A9-4253-B2C2-F1D05004A296Q43223779-655875F7-553B-46F3-8A19-689EEA9C5FE6Q43555422-A270D9DB-3070-44EF-AA85-F4C37AB04DBBQ44592739-EF4C1D88-F2E2-4443-8B7B-37379B81529DQ44663072-5B37A55D-BB3A-4115-A404-7863A716A60FQ44891091-37CC28D8-612F-45CF-B392-B937FE0897AFQ45866594-CF52E1FB-396C-49C5-806B-57E52ADAB69BQ45869559-49D97B0F-30C7-45BB-8B75-F047540D986EQ45870948-818F558E-F40C-4694-98B6-10B69AED2D75Q45872230-878F68D5-9806-4BF0-9269-6BF367C42D56
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vincenzo Cerullo
@ast
Vincenzo Cerullo
@en
Vincenzo Cerullo
@es
Vincenzo Cerullo
@nl
Vincenzo Cerullo
@sl
type
label
Vincenzo Cerullo
@ast
Vincenzo Cerullo
@en
Vincenzo Cerullo
@es
Vincenzo Cerullo
@nl
Vincenzo Cerullo
@sl
prefLabel
Vincenzo Cerullo
@ast
Vincenzo Cerullo
@en
Vincenzo Cerullo
@es
Vincenzo Cerullo
@nl
Vincenzo Cerullo
@sl
P1053
B-9075-2015
P106
P1153
6506518301
P21
P31
P3829
P496
0000-0003-4901-3796